View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 6, 2011

Enzo Discover Novel Target for Metabolic Bone Disease

Enzo Biochem has reported the discovery of new class of proteins that have been shown to inhibit the Wnt signalling pathway, and therefore mediate the development of a number of conditions, including metabolic bone disease. Enzo Biochem CEO Dr Elazar Rabbani announced at the WNT 2011 c

By cms admin

Enzo Biochem has reported the discovery of new class of proteins that have been shown to inhibit the Wnt signalling pathway, and therefore mediate the development of a number of conditions, including metabolic bone disease.

Enzo Biochem CEO Dr Elazar Rabbani announced at the WNT 2011 conference in Los Angeles that the team has identified a new target on a key modulator of the Wnt system that not only allows for development of novel antibodies for the modulation of this important pathway, but it has also identified a small peptide that can accomplish the same modulation without the need for antibodies.

“We believe that this exciting discovery opens up the possibility for the development of a new class of therapeutic products for the treatment of numerous important diseases, including cancer and metabolic disorders,” said Rabbani.

Anti-scelerostin anabolics are among the most exciting developments in the treatment of bone disorders, its has been shown that fluctuations in the level of these proteins has been shown to affect serious conditions as osteoporosis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology